BMX (Bone Marrow Tyrosine Kinase) Drug Discovery Landscape & Assay Solutions

  • By admin
  • 07 Aug 2026
  • Comments

Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology, Angiogenesis, and Solid Tumor Development.

TarMart Solution Ecosystem & Related Targets

Comprehensive reagent toolkit for BMX kinase drug discovery. Select your modality below:

Component / Network Product Description Product Link
Antigen (Wild-Type & Mutant) BMX Kinase Domain (aa 393-675) Recombinant Protein – Active & Kinase-Dead variants available. High purity (>95%), Endotoxin <1 EU/µg, Sequence Verified, HEK293 expressed. Also includes gatekeeper (T674I) and activation loop mutants verified by mass spec. View BMX Products
Gene Delivery BMX Full-Length ORF Lentivirus – CMV promoter, Puromycin selection, ≥10^8 TU/mL, for stable cell line generation and cellular phosphorylation assays. View BMX Products
Resistance Panel BMX Mutant Kinase Panel (Gatekeeper T674I, Activation Loop) – Site-directed mutagenesis, sequence verified by mass spectrometry, for resistance profiling. View BMX Products
Benchmark Ab Anti-BMX Recombinant Antibody – Sequence verified, high specificity for Western Blot, Flow Cytometry, and ELISA. View BMX Products
Validator BMX siRNA Set (3 unique sequences) – For knockdown verification and on-target specificity confirmation in cellular assays. View BMX Products
Related Target A BTK (Bruton's Tyrosine Kinase) – TEC family homolog; essential for kinase selectivity profiling and combination studies. View BTK Products
Related Target B TEC (Tyrosine Kinase expressed in Hepatocellular carcinoma) – Closest paralog; critical for subfamily off-target counter-screening. View TEC Products
Related Target C ITK (IL-2-Inducible T-cell Kinase) – TEC family kinase involved in T-cell signaling; required for cross-reactivity screening and immune safety assessment. View ITK Products
Related Target D AR (Androgen Receptor) – Downstream signaling node in BMX-driven prostate cancer; for resistance bypass and pathway synergy studies. View AR Products
Critical Assay Challenge The TarMart Advantage (Technical Spec)
High BTK Homology (Selectivity Screening) Matched BMX & BTK Kinase Domains (>95% purity, same batch production) for parallel IC50 determination; plus BTK, ITK, TEC, TXK homolog panel strictly verified by mass spec.
Resistance Profiling (Clinical Bypass) Single-point mutant panel (e.g., T674I gatekeeper, activation loop mutants) with strict sequence and purity verification; also covers dbSNP variants (rs35353387) and somatic mutations (e.g., lung large cell carcinoma).
Target Engagement Validation (Cellular Context) High-titer lentivirus (≥10^8 TU/mL) for stable cell line construction; validated siRNA for loss-of-function control; supports NanoBRET and CETSA assays.
Cross-species Evaluation Human/Mouse/Cyno ortholog BMX kinase domain proteins available (>95% purity, Sequence Verified) for preclinical PK/PD studies.
Lack of Kinase Assay Controls Purified Active & Kinase-Dead BMX proteins, clinical benchmark antibodies, and matched wild-type/mutant panels included as assay controls.

Live BMX R&D Tracker

Market data changes daily. Access the latest global pipeline status directly:

Global Clinical Landscape & Future Outlook

The therapeutic landscape for BMX (Bone Marrow Tyrosine Kinase, also known as ETK) is rapidly transitioning from non-selective TEC family inhibitors (e.g., dual BTK/BMX agents) toward highly selective small molecules designed to avoid BTK-mediated immunosuppression and bleeding risks. While BTK inhibitors have revolutionized B-cell malignancies, BMX emerges as a critical target in solid tumors—particularly castration-resistant prostate cancer (CRPC), triple-negative breast cancer, and glioma—where it drives androgen receptor (AR) signaling, angiogenesis, and tumor survival pathways. As first-generation pan-TEC inhibitors face safety limitations, the R&D focus is shifting toward BMX-selective degraders (PROTACs) and allosteric inhibitors that spare BTK activity. The next wave of development will prioritize CNS-penetrant formulations to address brain metastases and combination strategies with AR pathway inhibitors. Resistance mutations (e.g., gatekeeper T674I, somatic mutations such as those identified in lung large cell carcinoma) are driving the need for second-generation compounds and mutant-specific protein reagents.

Competitive Modality & Indication Snapshot

Modality Representative Players Key Indications Critical Assay Need (Why TarMart?)
Selective Small Molecule Inhibitor Johnson & Johnson, Emerging Biotechs, Academic Consortia CRPC, Solid Tumors, Glioma Selectivity Panel: BMX vs BTK/TEC/ITK Kinase Domains (need matched antigens and mutant proteins)
PROTAC / Degrader Emerging Biotechs, Academic–Industry Partnerships Refractory / Resistant Cancers Target Engagement & Degradation Assays (need full-length BMX lentivirus, stable cell lines, specific antibodies)
Pan-TEC / Dual Inhibitors Major Pharma (legacy programs) Hematological Malignancies, Initial Solid Tumor Proof-of-Concept Off-target Profiling (need TEC, ITK, TXK family panels; wild-type and mutant kinases)
Gene Therapy / siRNA Preclinical Research Institutions Cardiovascular, Inflammation Knockdown Verification (need validated BMX siRNA set for specificity confirmation)